Magdalena Dryglewska

Magdalena Dryglewska

Auto-generated profile, based on publicly available information

Magdalena Dryglewska

Department of Rheumatology and Connective Tissue Diseases, Medical University, Lublin, Poland

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2020 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
EWEwa Wielosz
Ewa Wielosz
MDMagdalena Dryglewska
Magdalena Dryglewska
MMMaria Majdan
Maria Majdan
Introduction: Anti-PM/Scl (a-PM/Scl) antibodies are found in different systemic autoimmune diseases such as polymyositis, dermatomyositis, systemic sclerosis (SSc) and overlap syndromes. According to literature, they are detected in approx. 2% of SSc patients, but their presence is more common...

1 June 2008 in Annales UMCS, Medicina
Verified
Journal Article
Open access
Bożena Targońska-StępniakBożena Targońska-Stępniak
Bożena Targońska-Stępniak
MMMaria Majdan
Maria Majdan
MDMagdalena Dryglewska
Magdalena Dryglewska
EKElżbieta Kimak
Elżbieta Kimak

14 July 2026 in Rheumatology
Verified
Journal Article
Open access
PDF file
DSDominika Szlichta
Dominika Szlichta
MDMagdalena Dryglewska
Magdalena Dryglewska
EŁEwa Łyś-Toporowska
Ewa Łyś-Toporowska
MMMaria Majdan
Maria Majdan
Introduction: Ankylosing spondylitis (AS) is a chronic inflammatory disease that can be managed with tumor necrosis factor (TNF) inhibitors. This study evaluated the effects of adalimumab, a TNF inhibitor, on inflammatory markers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Monitoring disease activity during therapy is important for assessing treatment response. Material and methods: We analyzed the medical history of 28 patients with confirmed AS, treated with adalimumab. The inflammatory markers neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), monocyte–lymphocyte ratio (MLR), CRP, ESR, and the Bath Ankylosing Spondylitis Disease Activity Index were assessed at the beginning of the observation (month 0) and after 3, 6, and 12 months of therapy. Results: The mean NLR value after 3 months of treatment was 1.48 (95% confidence interval, CI: 0.92–2.03, p < 0.001), after 6 months was 1.48 (95% CI: 0.92–2.12, p < 0.001), and after 12 months was 1.67 (95% CI: 1.08–2.30, p < 0.001). Mean MLR value after 3 months of treatment was 0.07 (95% CI: 0.03–0.13, p = 0.005), after 6 months was 0.05 (95% CI: 0.00–0.11, p = 0.101), and after 12 months was 0.06 (95% CI: 0.01–0.11, p = 0.047), showing statistical significance only after 3 and 12 months. The mean PLR value after 3 months of treatment was 52.8 (95% CI: 30.1–79.60, p < 0.001), after 6 months was 65.50 (95% CI: 31.60–83.90, p < 0.001), and after 12 months was 68.80 (95% CI: 42.70–93.70, p < 0.001). Conclusions: Neutrophil–lymphocyte ratio may be a useful marker of inflammation in patients with AS. Monocyte–lymphocyte ratio and PLR require further investigation. Peripheral blood tests are simple and inexpensive to perform, making hematological markers promising tools for monitoring inflammatory diseases.